Biogen Halts Plans to Develop Tysabri for Stroke After Phase IIb Trial Flop Post author:Sam Post published:February 6, 2018 Post category:BioPharma Natalizumab did not demonstrate improvement in clinical outcomes compared to placebo. Source: BioSpace You Might Also Like Study Reveals Huge Potential for mRNA Drug Targets March 18, 2018 Frazier-Backed Mavupharma Scores $20M to Fund STING Program November 28, 2017 Five Prime Tanked on Early Peek of Lead Drug Data November 7, 2017
